Drug intelligence / Profile preview

Periogen

Development stage: Unknown
Lead developer: Periogen
Modality: Recombinant Proteins and Enzymes
Administration: Implantation

Overview

Periogen is a therapeutic product composed of recombinant human Platelet-Derived Growth Factor (rhPDGF) and beta-tricalcium phosphate (beta-TCP). It is designed to promote gingival healing and correct periodontal defects, specifically intrabony periodontal defects, by stimulating tissue regeneration and providing a scaffold for bone formation.

Brand names: Periogen
Other names: rhPDGF-BB + beta-TCP

Targets

Hydroxyapatite

Beyond the preview

Go deeper on Periogen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Periogen.

Explore the full profile